Ratings Sartorius Stedim Biotech S.A. OTC Markets

Equities

SRTOY

US80386Y1010

Market Closed - OTC Markets Other stock markets 02:21:13 2024-06-20 pm EDT			5-day change	1st Jan Change
17.05 ^USD	-12.56%		-12.56%	-37.84%

Jun. 20	Sartorius stabilizes after previous day's price slide	DP
Jun. 19	Sartorius on the downswing again - low since 2020 is approaching	DP

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's high margin levels account for strong profits.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 44.12 times its estimated earnings per share for the ongoing year.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Revenue estimates are regularly revised downwards for the current and coming years.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SARTORIUS STEDIM BIOTECH S.A.	-37.84%	16.35B	-
ABBOTT LABORATORIES	-3.18%	185B	C+
MEDTRONIC PLC	-2.68%	105B	C
BECTON, DICKINSON AND COMPANY	-2.23%	68.9B	A
DEXCOM, INC.	-6.46%	46.16B	B-
HOYA CORPORATION	+5.33%	40.75B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+20.09%	31.11B	B
TERUMO CORPORATION	+11.34%	24.26B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-6.67%	23.94B	A-
ZIMMER BIOMET HOLDINGS, INC.	-12.70%	21.86B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes